Phase 3 N=53 Evaluation of the Tympanostomy Tube Delivery System
Otitis Media With Effusion · Acute Otitis Media
Primary: Safety of Tympanostomy Tube (TT) Delivery System — 0.0 percentage of ears
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
Phase 3 N=70 Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
Erythema · Rosacea
Primary: Composite Success — 14.3; 5.7 percentage of subjects
Phase 3 N=526 Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)
Insomnia
Primary: Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period — 382.14; 382.77; 394.83; 351.40 Minutes — p=<0.0001
Phase 3 N=121 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events — 48.8; 10.7; 8.3; 5.8 percentage of participants
Phase 3 N=157 Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
Pulmonary Disease, Chronic Obstructive
Primary: Adjusted Mean Endurance Time After 6 Weeks — 354.33; 396.31; 391.45 seconds — p=0.0018
Phase 3 N=151 Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
Pulmonary Disease, Chronic Obstructive
Primary: Adjusted Mean Endurance Time After 6 Weeks — 369.81; 421.58; 420.72 seconds — p=0.0002
Phase 3 N=259 A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
Sleep Initiation and Maintenance Disorder; Elderly · Mental Disorder · Dyssomnias
Primary: Number of Participants Who Experience at Least One Adverse Event (AE) — 115; 116 Participants
Phase 3 N=285 Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
Asthma
Primary: Number of Patients With Drug-related Adverse Events — 3; 6; 10 participants
Phase 3 N=23 Exhaled Levels of Nitric Oxide
Tetraplegia · Asthma
Primary: Exhaled Levels of Nitric Oxide — 17.27; 19.83; 15.025; 3.70 ppb (parts per bilion)
Phase 3 N=133 Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)
Peripheral Arterial Disease
Primary: Successful Revascularization — 92.0 percentage of lesions — p=<0.05
Phase 3 N=925 Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
Severe Nodular Acne
Primary: Co-primary Outcome 1: Change From Baseline in Total Nodular Lesion Count (Facial and Truncal) — -17.01; -16.52 Lesions — p=0.5077
Phase 3 N=55 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Opioid Dependence · Heroin Dependence
Primary: Opiate Use Measured by Urine Toxicology Results — 9; 10 Percent of total urine samples
Phase 3 N=300 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 11.79; 10.28 month
Phase 3 N=784 Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
Rhinitis, Allergic · Conjunctivitis
Primary: Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) — 7.70; 6.88; 6.41; 8.46…